Hui-Ying Liu, Xiao-Fei Bi, Ya-Jun Wang, Feng-Jie Xie, Hong Zhang, Yu-Cheng Zhu, Yan Zhang, Zhi-Hui Wang, Di Wu, Huan Meng, Yi-Lu Lin, Lin-Qiong Liu, Shu-Xiao Qiu, Yan Gao, Kai Kang, Yang Gao
BACKGROUND: Initial choices of antimicrobial therapy for most cases of community-acquired pneumonia (CAP) in children under 5 years of age are typically based on local epidemiology, risk factors assessment, and subsequent clinical parameters and positive cultures, which can lead to the underdiagnosis and underestimation of lung infections caused by uncommon pathogens. Contezolid, an orally administered oxazolidinone antibiotic, gained approval from the National Medical Products Administration (NMPA) of China in June 2021 for managing complicated skin and soft tissue infections (cSSTI) caused by staphylococcus aureus (SA), streptococcus pyogenes, or streptococcus agalactis...
2024: Frontiers in Pediatrics